alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5

<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
REGISTRANT'S FORM 10-Q FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
INCLUDED IN SUCH REPORT.
</LEGEND>

       
<S>                     <C>
<PERIOD-TYPE>           3-MOS
<FISCAL-YEAR-END>       DEC-31-1999
<PERIOD-END>            MAR-31-1999

<CASH>                          43,842,359 
<SECURITIES>                          0    
<RECEIVABLES>                   40,142,290 
<ALLOWANCES>                       166,162 
<INVENTORY>                    147,009,826 
<CURRENT-ASSETS>                      0    
<PP&E>                          62,035,378 
<DEPRECIATION>                  28,083,853 
<TOTAL-ASSETS>                 275,783,574 
<CURRENT-LIABILITIES>                 0    
<BONDS>                               0    
<COMMON>                              0    
<PREFERRED-MANDATORY>                 0    
<PREFERRED>                           0    
<OTHER-SE>                     163,784,098 
<TOTAL-LIABILITY-AND-EQUITY>   275,783,574 
<SALES>                         97,402,569 
<TOTAL-REVENUES>                97,402,569 
<CGS>                           79,002,845 
<TOTAL-COSTS>                   79,002,845 
<OTHER-EXPENSES>                 2,551,745 
<LOSS-PROVISION>                      0    
<INTEREST-EXPENSE>                    0    
<INCOME-PRETAX>                 15,847,979 
<INCOME-TAX>                          0    
<INCOME-CONTINUING>             15,847,979 
<DISCONTINUED>                        0    
<EXTRAORDINARY>                       0    
<CHANGES>                             0    
<NET-INCOME>                    15,847,979 
<EPS-PRIMARY>                        38.84 
<EPS-DILUTED>                        38.84 

        

</TABLE>
§ 516.25 Refusal to grant MUMS-drug designation. ( a ) FDA will refuse to grant a request for MUMS-drug designation if any of the following reasons apply: ( 1 ) The drug is not intended for use in a minor species or FDA determines that there is insufficient evidence to demonstrate that the drug is intended for a minor use in a major species.
( 2 ) The drug is the same drug in the same dosage form for the same intended use as one that already has a MUMS-drug designation but has not yet been conditionally approved or approved.
( 3 ) The drug is the same drug in the same dosage form for the same intended use as one that is already conditionally approved or approved. A drug that FDA has found to be functionally superior is not considered the same drug as an already conditionally approved or approved drug even if it is otherwise the same drug in the same dosage form for the same intended use.
( 4 ) The sponsor has failed to provide: ( i ) A credible scientific rationale in support of the intended use,
( ii ) Sufficient information about the product development plan for the drug, its dosage form, and its intended use to establish that adherence to the plan can lead to successful drug development in a timely manner, and
( iii ) Any other information required under § 516.20.
( b ) FDA may refuse to grant a request for MUMS-drug designation if the request for designation contains an untrue statement of material fact or omits material information.
###### Editorial Note on Part 312

#### Editorial Note:

Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

#### § 312.66 Assurance of IRB review.

An investigator shall assure that an IRB that complies with the requirements set forth in part 56 will be responsible for the initial and continuing review and approval of the proposed clinical study. The investigator shall also assure that he or she will promptly report to the IRB all changes in the research activity and all unanticipated problems involving risk to human subjects or others, and that he or she will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.

[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]
Exhibit 4.2


 


Addendum
no. 2 to research and license agreement dated april 8, 2010, as amended on june 25, 2012 


 


This Addendum No. 2 to that certain
Research and License Agreement dated April 8, 2010, as amended on June 25, 2012 (the "Agreement"; and this "Addendum"
respective) is made and entered into as of this 19th day of March, 2017, by and among Todos Medical Ltd., a company
organized and existing under the laws of the State of Israel having its principal offices at 1 Hamada Street, Rehovot, Israel (the
“Company”), B.G. Negev Technologies and Applications Ltd. and Mor Research Applications Ltd. (collectively
the “Licensors”)


 


WHEREAS, the Parties wish
to amend the Agreement, a copy of which is attached hereto as Exhibit A as more fully detailed in this Addendum;


 


 


NOW THEREFORE, in consideration
of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein
contained, and intending to be legally bound hereby, the Parties agree as follows:


 


		1.	The preamble to this Addendum and exhibits attached hereto form an integral
part hereof.



		2.	All capitalized terms herein shall have the meaning ascribed to them in the
Agreement, unless otherwise defined herein.



		3.	Section 4.1.3 of the Agreement shall be replaced with the following:



 


"4.1.3Minimum
Royalties. For as long as this Agreement is in force and effect, the Company shall pay the Licensors an annual minimum
royalty ("Annual Minimum Royalty") as follows:


 


for the year 2015: USD 10,000;


for the year 2016: USD 25,000


for the year 2017 and for
each full calendar year thereafter that this Agreement is in force and effect: USD 50,000 per year (it being noted that for a partial
year a pro-rata payment shall be due as set forth in Section 4.2.3 below).


 


The Minimum Annual Royalty
paid each calendar year as aforesaid shall be reduced by the Running Royalties and Sublicense Consideration paid to Licensors with
respect to such specific calendar year."


 


		4.	The Parties agree that notwithstanding the terms of the Agreement including
Section 4.1.3 (as replaced pursuant to Section 3 above) and Section 4.2.3, payment of the Annual Minimum Royalty for the years
2015, 2016 and 2017 (in a total amount of USD 85,000 plus applicable VAT) shall be paid by Company to Licensors on the earlier
of (i) August 1, 2017; and (ii) within three (3) days following the date on which the Company shall have received an equity investment
net proceeds pursuant a financing round of not less than USD 10,000,000.



 


		5.	All other terms of the Agreement shall remain unchanged.



 


 


IN WITNESS WHEREOF, the
Parties hereto have executed this Addendum on the date first above written.


 


 










	Todos Medical Ltd.		B.G. Technologies and Applications Ltd.	 	Mor Research Applications Ltd.
<PAGE>   1

                                                                   EXHIBIT 21.1



                          SUBSIDIARIES OF THE COMPANY


<TABLE>
<CAPTION>
    Subsidiary                                          State of Incorporation
    ----------                                          ----------------------

<S>                                                     <C>
Forcenergy International Inc.                                   Delaware

Forcenergy Phenix Marin Corp.                            British Virgin Islands

Forcenergy Gryphon B.V                                         Netherlands

Forcenergy Resources Inc.                                         Texas

Forcenergy Onshore Inc.                                         Delaware

Forcenergy GOM Inc.                                             Delaware

Forcenergy Ltd.                                              Cayman Islands

Forcenergy Drilling Inc.                                        Delaware

Edisto Energy Inc.                                                Texas

Edisto Canada, Inc.                                              Canada

Mint Holding Company                                              Texas

Forcenergy Australia Pty. Ltd.                                  Australia

Forcenergy Gabon Ltd.                                            Liberia

Forcenergy Invest AB                                             Sweden

FAB Holding Co., L.L.C                                          Delaware

Forcenergy AB                                                    Sweden
</TABLE>
OSLDPS Information Bulletin

No. 33 May 4, 2001

TO: All State Administrative Agency Heads

All State Administrative Agency Points of Contact

FROM: C.H. “Butch” Straub, II

Director

SUBJECT: Revisions to OSLDPS Web Site and the Impact on Users of the On-Line Data

Collection Tool

The Office for State and Local Domestic Preparedness Support (OSLDPS) plans to activate an

enhanced web site shortly. This Information Bulletin addresses the impact of this change on users

of the On-Line Data Collection Tool, and is intended to minimize any resulting confusion. Please

ensure that this information is provided to all first responder and public health jurisdictions

participating in your State’s assessment process. 

While the look and feel of the new web site will be much different from the one it replaces, the

OSLDPS home page will continue to be accessible at: www.ojp.usdoj.gov/osldps. Additionally,

the On-Line Data Collection Tool will still be located in the following three areas: “What’s New,”

“Grant Programs & Equipment,” and “Exercises & Assessments.” Links to these areas can be

found on the home page. However, the URLs for these links may differ from those on the old

web site. To avoid any problems when the new site is activated, OSLDPS recommends that users

who previously established bookmarks or shortcuts directly to these areas on the old web site

initially go to the OSLDPS home page. They may then recreate any desired bookmarks or

shortcuts with the correct URLs. 

For technical assistance with On-Line Data Collection Tool, you may continue to contact the OJP

toll-free help line at 1-888-549-9901. Assistance with the public health assessment may be

obtained by calling the Centers for Disease Control and Prevention help line at 1-800-747-7649. 

You may also contact your OSLDPS program manager for additional information and assistance

related to conduct of the needs assessment and development of your three-year state strategy.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7115 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7115

   To permit individuals 70 years of age or older to opt out of jury 
       service in the Superior Court of the District of Columbia.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 29, 2024

  Ms. Norton introduced the following bill; which was referred to the 
               Committee on Oversight and Accountability

_______________________________________________________________________

                                 A BILL

 
   To permit individuals 70 years of age or older to opt out of jury 
       service in the Superior Court of the District of Columbia.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``District of Columbia Superior Court 
Jury Duty for Seniors Opt Out Act of 2024''.

SEC. 2. PERMITTING INDIVIDUALS 70 YEARS OF AGE OR OLDER TO OPT OUT OF 
              JURY SERVICE IN SUPERIOR COURT OF THE DISTRICT OF 
              COLUMBIA.

    Section 11-1908(b), District of Columbia Official Code, is 
amended--
            (1) by striking ``or (4)'' and inserting ``(4)''; and
            (2) by striking the period at the end of the first sentence 
        and inserting ``; or (5) excluded by the Court upon the request 
        of the individual if the individual is 70 years of age or 
        older.''.
                                 <all>
```
Office of Grants and Training 

Preparedness Directorate 

U.S. Department of Homeland Security 

Washington, DC 20531 

 

Office of Grants and Training Information Bulletin 

No. 203 March 17, 2006 

TO: All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 All State Homeland Security Directors 

FROM: Tracy A. Henke, Assistant Secretary, Office of Grants and Training (G&T) 

 

SUBJECT: Use of FY 2004 and 2005 Homeland Security Grant Program (HSGP) Funds in 

Support of the 2006 Hurricane Preparedness Exercises 

In accordance with Secretary Chertoff’s March 1, 2006 letter to the Governors of each of the 

nation’s coastal states from Maine to Texas, the Department of Homeland Security (DHS) 

Preparedness Directorate’s Office of Grants and Training (G&T) is sponsoring five Hurricane 

Preparedness Exercises in advance of the 2006 hurricane season. These exercises are designed to 

increase the preparedness of Eastern Seaboard and Gulf Coast States for the 2006 hurricane 

season that begins on June 1, 2006. Also, as indicated in the March 1 letter, G&T is updating the 

FY 2004 and 2005 HSGP grant guidance to provide the flexibility needed for full state and urban 

area involvement in these important and time-sensitive exercises. 

While FY 2006 HSGP funds can be used to support catastrophic natural disaster activities, 

FY 2006 funds are not currently available, and prior fiscal year HSGP grants cannot be used for 

natural disaster activities. Consequently, prior to this update, States and urban areas did not have 

HSGP funds that could be used for the Hurricane Preparedness Exercises 

This update allows states and urban areas (as defined under the Urban Areas Security Initiative 

(UASI) for FY 2005 and FY 2006) to expend FY 2004 and 2005 HSGP funds on activities 

associated with participation in the 2006 Hurricane Preparedness Exercises. Specifically, FY 

2004 and 2005 funds from UASI and the State Homeland Security Program (SHSP) may be used 

in support of the 2006 Hurricane Preparedness Exercises. As a reminder, Emergency 

Management Performance Grants (EMPG) funds may be used to support these activities as well. 

This grant guidance update applies only to the use of FY 2004 and 2005 HSGP funding for the 

2006 Hurricane Preparedness Exercises. This guidance does not expand other allowable exercise 

activities outlined in the FY 2004 and 2005 HSGP guidance. 

Questions on this information bulletin may be directed to your G&T Preparedness Officer or the 

Centralized Scheduling and Information Desk at askcsid@dhs.gov, 1-800-368-6498.
# LI2019279EN.01001101.xml

| 31.10.2019 | EN | Official Journal of the European Union | LI 279/11 |
| --- | --- | --- | --- |

31.10.2019

EN

Official Journal of the European Union

LI 279/11

---

Corrigendum to Decision 2019/1798of the European Parliament and of the Council of 14 October 2019 appointing the European Chief Prosecutor of the European Public Prosecutor’s Office

(
  Official Journal of the European Union L 274 of 28 October 2019
  )

On the cover, in the table of contents, and on page 1, in the title:

for:

‘Decision 2019/1798of the European Parliament and of the Council of 14 October 2019 appointing the European Chief Prosecutor of the European Public Prosecutor’s Office’,

read:

‘Decision (EU) 2019/1798 of the European Parliament and of the Council of 23 October 2019 appointing the European Chief Prosecutor of the European Public Prosecutor’s Office’;

on page 2:

for:

‘Done at Luxembourg, 14 October 2019.’,

read:

‘Done at Strasbourg, 23 October 2019.’.

---
§ 520.1900 Primidone. ( a ) *Specifications.* Each tablet contains 50 or 250 milligrams of primidone.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter. ( 1 ) No. 069043 for use of 250 milligram tablets.
( 2 ) No. 054771 for use of 50 and 250 milligram tablets.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Twenty-five milligrams of primidone per pound of body weight (55 milligrams per kilogram of body weight) daily.
( 2 ) *Indications for use.* For the control of convulsions associated with idiopathic epilepsy, epileptiform convulsions, viral encephalitis, distemper, and hardpad disease that occurs as a clinically recognizable lesion in certain entities in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[42 FR 61594, Dec. 6, 1977, as amended at 43 FR 55386, Nov. 28, 1978; 46 FR 8467, Jan. 27, 1981; 46 FR 57477, Nov. 24, 1981; 53 FR 40727, Oct. 18, 1988; 56 FR 37473, Aug. 7, 1991; 62 FR 35076, June 30, 1997; 78 FR 21060, Apr. 9, 2013; 79 FR 28827, May 20, 2014; 83 FR 48946, Sept. 28, 2018]
CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In connection with the Quarterly  Report of Tonga Capital  Corporation (the
"Company") on Form 10-QSB for the period ending September 30, 2005 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report").  I,
Jeffrey  Ploen,  Chief  Executive  Officer  and Chief  Financial  Officer of the
company,  certify,  pursuant  to 18 USC  Section  1350,  as adopted  pursuant to
Section 906 of the  Sarbanes-Oxley Act of 2002, that to the best of my knowledge
and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information contained in the Report fairly presents, in all
                material respects, the financial condition and results of
                operations of the Company.




                                         /s/ Jeffrey Ploen
                                         --------------------------------
                                         Jeffrey Ploen, CEO/CFO
Dated: November 15, 2005
<PAGE>
                                                                   EXHIBIT 23.01


                       CONSENT OF INDEPENDENT ACCOUNTANTS


We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No. 33-92902, No. 333-14323, No. 333-18871, No.
333-42819, No. 333-46875, No. 333-50623, No. 333-62195, No. 333-71923, No.
333-80965, No. 333-89165, No. 333-33952, No. 333-40344, No. 333-41388, No.
333-45442, No. 333-55398 and No. 333-62492) and Form S-3 (No. 333-72804) of HNC
Software Inc. of our report dated January 23, 2002, except as to Note 16, to
which the date is March 21, 2002, relating to the financial statements, which
appears in this Form 10-K.




San Diego, California
March 22, 2002
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-6129

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

THERESA MUBANG,

Defendant - Appellant.

Appeal from the United States District Court for the Eastern District of Virginia, at 

Alexandria. Leonie M. Brinkema, District Judge. (1:01-cr-00252-LMB-1)

Submitted: April 19, 2018 Decided: April 24, 2018

Before GREGORY, Chief Judge, and THACKER and HARRIS, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Theresa Mubang, Appellant Pro Se. Leonard Oliver Evans, III, OFFICE OF THE UNITED 

STATES ATTORNEY, Alexandria, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Theresa Mubang seeks to appeal her judgment of conviction. In criminal cases, the 

defendant must file the notice of appeal within 14 days after the entry of judgment. Fed. 

R. App. P. 4(b)(1)(A). With or without a motion, upon a showing of excusable neglect or 

good cause, the district court may grant an extension of up to 30 days to file a notice of 

appeal. Fed. R. App. P. 4(b)(4); United States v. Reyes, 759 F.2d 351, 353 (4th Cir. 1985).

The district court entered judgment on October 5, 2001. Mubang filed the notice of 

appeal on January 29, 2018, nearly 17 years after entry of judgment. In the notice, Mubang 

sought an order vacating that portion of the criminal judgment ordering restitution. 

Because Mubang has previously sought an order vacating the restitution order, we conclude 

that this is one of those circumstances when this court may invoke its sua sponte authority 

to dismiss the appeal as untimely. See United States v. Oliver, 878 F.3d 120, 128-30 (4th 

Cir. 2017) (stating that court may invoke sua sponte authority to dismiss an untimely direct 

criminal appeal after defendant has pursued collateral relief of the same judgment). 

Because Mubang failed to file a timely notice of appeal or to obtain an extension or 

reopening of the appeal period, we dismiss the appeal. We dispense with oral argument 

because the facts and legal contentions are adequately presented in the materials before this 

court and argument would not aid the decisional process.

DISMISSED
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          APR-30-1997
<PERIOD-START>                             MAY-01-1996
<PERIOD-END>                               APR-30-1997
<CASH>                                         135,039
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               146,989
<PP&E>                                         340,986
<DEPRECIATION>                                   9,710
<TOTAL-ASSETS>                                 478,265
<CURRENT-LIABILITIES>                          240,860
<BONDS>                                              0
<PREFERRED-MANDATORY>                          197,750
<PREFERRED>                                          0
<COMMON>                                     1,648,084
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   478,265
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,044,516
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,044,516)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,044,516)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,044,516)
<EPS-PRIMARY>                                    (.13)
<EPS-DILUTED>                                    (.13)
        

</TABLE>